Assistant Director Flow and Image Cytometry Roswell Park Cancer Institute

目前的申请寻求汉斯明德曼，博士谁担任工资支持 罗斯威尔流式细胞术和图像细胞术共享资源（FICSR）助理主任 帕克癌症研究所。该职位于2007年设立，负责监督 可使用的各种成像（共聚焦、活细胞成像）和流式细胞仪平台 设施，建立和实施一个程序，然后新颖的ImageStream技术， 在这些领域的合作和协商中运用他的广泛经验， FICSR调查员用户群。拥有超过30年的临床应用经验， 和图像细胞术（25年在罗斯韦尔公园癌症研究所），博士明德曼在他的整个 职业生涯与研究所的许多研究人员在NIH资助的项目上合作。的 肿瘤免疫学和免疫治疗（TII）癌症中心支持补助金（CCSG）计划，共同- 由Odunsi博士领导，他是该应用程序的单位主任，是 FICSR和许多NIH资助的研究人员在这个项目中积极合作， 根据PAR16 - 025资金的目的，与Minderman博士协商 机会具体来说，在Dr 明德曼的方向在许多研究人员的研究工作中发挥了重要作用， TII和卵巢孢子项目由Odunsi博士领导。在提供TII和 2015年12月，RPCI的尖端细胞仪技术的SPORE计划成员 购买了一台Helios细胞仪，可以对小细胞进行高维多重表型分析。 样本大小，如肿瘤微环境的活检。明德曼医生会用他的 在建立和实施非常成功的ImageStream计划方面的专业知识， 咨询并积极与Odunsi博士的研究小组合作， Helios技术以及开发和验证其应用。

The current application seeks salary support for Hans Minderman, PhD who serves as the Assistant Director of the Flow and Image Cytometry Shared Resource (FICSR) of the Roswell Park Cancer Institute. This position was created in 2007 to oversee the research applications of the various imaging (confocal, live cell imaging) and flow cytometry platforms available in the facility, to establish and implement a program for the then novel ImageStream technology and to apply his extensive experience in these areas in collaborations and consultations with the FICSR investigator user base. With over 30 years of experience in clinical applications of flow and image cytometry (25 years at Roswell Park Cancer Institute), Dr Minderman throughout his career has collaborated with many investigators at the Institute on NIH funded projects. The tumor immunology & immunotherapy (TII) Cancer Center Support Grant (CCSG) program, co- led by Dr Odunsi, who serves as the unit director on this application, is the major user base of the FICSR; and numerous NIH-funded researchers in this program actively collaborate and consult with Dr Minderman commensurate with the purpose of the PAR16-025 funding opportunity. Specifically, the ImageStream cytometry applications developed under Dr Minderman’s direction play an important role in the research efforts of many researchers in the TII and ovarian SPORE programs led by Dr Odunsi. In the ongoing effort to provide the TII and SPORE program members with cutting edge cytometry technology, RPCI in December 2015 purchased a Helios cytometer which enables high dimensional multiplex phenotyping of small sample sizes such as biopsies of the tumor microenvironment. Dr Minderman will apply his expertise in setting up and implementing the highly successful ImageStream program to consulting and actively collaborating with Dr Odunsi’s research group to implementing the Helios technology and developing and validating its applications.